Technological Advances In Genomic Biomarkers: A Defining Factor in the Genomic Biomarker Market’s Growth Trajectory
The genomic biomarker market size is expected to see rapid growth in the next few years. It will grow to $18.93 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to growing focus on the availability of personalized medications, rising occurrences of cardiovascular diseases, rising number of patients with neurological diseases, growing investments in genomic research, and growing adoption of personalized nutrition. Major trends in the forecast period include technological advancements, digital health, artificial intelligence, machine learning, and personalized medicine.
Get Your Free Sample of The Global Genomic Biomarker Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20557&type=smp
What key drivers have fueled the genomic biomarker market’s development over the years?
The increasing prevalence of chronic diseases is expected to propel the growth of the genomic biomarker market going forward. Chronic diseases are long-lasting health conditions that persist over time and often progress slowly. The increasing prevalence of chronic diseases is due to aging populations and rising rates of lifestyle-related conditions such as obesity and diabetes. Genomic biomarkers enable early detection and personalized prevention strategies for chronic diseases by identifying genetic predispositions and tailoring interventions. This proactive approach helps reduce prevalence by targeting at-risk individuals before disease onset. For instance, in September 2023, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, each year, there are 41 million deaths worldwide, accounting for 74% of all fatalities attributed to chronic diseases. This includes 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Therefore, the increasing prevalence of chronic diseases drives the growth of genomic biomarkers.
What is the segmentation for the genomic biomarker market?
The genomic biomarker market covered in this report is segmented –
1) By Type: Predictive Biomarkers, Prognostic Biomarkers
2) By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Other Disease Indications
3) By Validation: Analytical Validation, Clinical Validation, Clinical Utility
4) By End-User: Hospitals, Diagnostic Centers, Research Laboratories, Other End Users
Subsegments:
1) By Predictive Biomarkers: Genetic Biomarkers For Disease Susceptibility, Pharmacogenomic Biomarkers For Drug Response, Early Detection Biomarkers For Disease Prediction, Biomarkers For Treatment Response Prediction
2) By Prognostic Biomarkers: Biomarkers For Disease Progression, Biomarkers For Outcome Prediction, Survival And Recurrence Biomarkers, Biomarkers For Treatment Efficacy And Prognosis
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/genomic-biomarker-global-market-report
Who are the most influential companies in the genomic biomarker market?
Major companies operating in the genomic biomarker market are Pfizer Inc., Roche Diagnostics, Thermo Fisher Scientific Inc., Merck KGaA, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., Foundation Medicine Inc., QIAGEN N.V., Almac Group Ltd., Myriad Genetics Inc., Invitae Inc., Guardant Health Inc., Novogene Inc., Twist Bioscience Corp., NanoString Technologies Inc., Quanterix Corp., Personalis Inc., GENEWIZ Inc., Agena Bioscience Inc., Creative Diagnostics Ltd., OncoDNA SA, Genome Life Sciences Ltd., Epigenomics AG.
What are the top industry trends projected to impact the genomic biomarker market?
Major companies operating in the genomic biomarker market are focusing on developing advanced products, such as advanced liquid biopsy assays, to enable comprehensive genomic profiling of solid tumors. A liquid biopsy assay is a diagnostic test that analyzes genetic material, typically circulating tumor DNA (ctDNA), from a blood sample to detect and monitor cancer. Identifying genomic biomarkers can provide information about specific mutations, gene expression profiles, or other genetic alterations associated with cancer. For instance, in November 2023, Illumina Inc., a US-based biotechnology company, launched an advanced liquid biopsy assay, the TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2), for comprehensive genomic profiling of solid tumors. The assay offers enhanced analytical sensitivity by detecting low-frequency variants with just 20 ng of cell-free DNA, down from 30 ng. It delivers results in under four days, greatly accelerating genomic profiling compared to traditional methods. The streamlined workflow and forthcoming automation will simplify lab integration and boost efficiency.
What are the major regional insights for the genomic biomarker market, and which region holds the top position?
North America was the largest region in the genomic biomarker market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Genomic Biomarker Market Report 2025 Offer?
The genomic biomarker market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
A genomic biomarker is a specific genetic sequence or molecular characteristic found in an individual's genome that can assess disease risk, predict disease progression, or determine response to a particular treatment. These biomarkers are often used in personalized medicine to tailor treatments based on an individual's genetic profile.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20557
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Comments
Post a Comment